Fosaprepitant and Aprepitant for Chemotherapy-Induced Nausea and Vomiting in Children

Marcia L. Buck, PharmD, FCCP, FPPAG, BCPPS

Disclosures

Pediatr Pharm. 2018;24(6) 

In This Article

Summary

The use of aprepitant and fosaprepitant has been a significant step in reducing the nausea and vomiting associated with chemotherapy administration. Over the past two years, several consensus statements and guidelines for the prevention of CINV in pediatric patients have been updated to include their use. New research with fosaprepitant and its approval by the FDA further support its routine use for moderately or highly emetogenic chemotherapy.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....